Retatrutide is a next-generation peptide medicine being researched for its potential role in weight management and metabolic health. It’s attracting attention because it works on three hormone pathways at once:
-
GLP-1 – affects appetite and glucose control
-
GIP – helps insulin response
-
Glucagon – may increase energy use and fat breakdown
This triple-action mechanism sets it apart from earlier medicines that target only one or two pathways.
What Have Clinical Studies Found?
Weight Loss Results in Clinical Trials
Published research from a Phase 2 trial shows that adults with obesity who received weekly injections of retatrutide experienced significant weight loss over 48 weeks. Higher doses were associated with larger reductions in body weight:
-
Participants on higher doses (8 mg and 12 mg) lost up to 24.2% of their body weight at 48 weeks compared with placebo. PubMed+1
👉 Read the peer-reviewed trial results:
🔗 Triple-Hormone Receptor Agonist Retatrutide for Obesity – Phase 2 Trial (full abstract on PubMed) PubMed
A systematic review of randomized controlled trials also confirmed that retatrutide significantly reduces body weight, waist circumference and fasting glucose compared with placebo. PubMed
How Was Retatrutide Studied?
In clinical research:
-
Retatrutide was given once-weekly as a subcutaneous injection
-
Doses ranged from 1 mg to 12 mg per week
-
Many trials used dose escalation — starting low and increasing gradually to improve tolerability and reduce side effects (such as nausea) during the early weeks. PubMed+1
These dosing regimens were part of structured research protocols and not recommendations for general use.
Benefits Beyond Weight Loss
Improvements in Liver Fat
A substudy published in Nature Medicine showed that retatrutide produced large reductions in liver fat (an important marker of metabolic health) in people with metabolic dysfunction-associated steatotic liver disease (MASLD). Higher doses produced greater reductions than lower doses. Nature
📄 Read the liver fat study:
🔗 Triple Hormone Receptor Agonist Retatrutide for MASLD – Nature Medicine Nature
Safety and Side Effects
Across studies, retatrutide’s safety profile has been broadly similar to other drugs targeting incretin pathways:
-
Most common side effects include nausea, vomiting and diarrhoea
-
Side effects were generally mild to moderate and tended to occur during the early dose escalation period. PubMed
Longer-term safety and rare events are still being evaluated in ongoing research.
What This Means for You
Based on current evidence:
-
Retatrutide has shown substantial, dose-dependent weight loss in clinical research. PubMed
-
Doses studied have ranged from 1 mg up to 12 mg per week in structured trials. PubMed
-
It may offer additional benefits like reduced liver fat, though more research is needed. Nature
-
Its safety profile so far aligns with expectations, but further data from larger Phase 3 studies is needed. PubMed
Retatrutide remains investigational and is not yet approved by major regulators for general use.
Australian Regulatory Disclaimer
Important Notice (Australia):
Retatrutide is an investigational medicine and is not approved by the Therapeutic Goods Administration (TGA) for use in Australia. The information in this article is provided for educational and informational purposes only. It is not medical advice and should not be used to diagnose, treat, cure or prevent any condition. Always seek guidance from a qualified healthcare professional before considering any medication or treatment.
